Abbott’s world-leading¹ FreeStyle Libre portfolio of continuous glucose monitors has revolutionized the way roughly 6 million people worldwide manage their diabetes². And now the technology that powers the best-selling medical device in history will be available to U.S. consumers with and without diabetes through two over-the-counter CGM systems cleared by the FDA.

Lingo, our consumer biowearable first announced during Chairman and CEO Robert Ford’s keynote at CES, allows us to expand beyond diabetes care and enter a new market: consumers who are looking to improve their overall health and wellness. Unlike health- and fitness-focused wearable devices, Lingo truly monitors what’s happening inside your body via a tiny filament that rests just under the skin of the upper arm. The Lingo biosensor, which can be worn for 14 days, tracks blood glucose levels, while its accompanying app provides personalized, real-time insights and customized coaching to help people create healthy eating habits, retrain their metabolism and improve their overall well-being.

Lingo launched in the United Kingdom in early 2024, and we plan to make it available to U.S. consumers in the summer of 2024.

A Growing Libre Portfolio

The FDA also cleared Libre Rio, Abbott’s first over-the-counter CGM system for people with diabetes in the United States. Libre Rio is designed for people ages 18 years and older with Type 2 diabetes who do not use insulin and typically manage their diabetes through lifestyle modifications.

While FreeStyle Libre systems have been available over the counter in more than 50 countries over the past decade, they have been available only through prescription in the U.S. By removing the prescription requirement, Libre Rio may make it easier for Americans with diabetes to try a CGM and begin to see progress toward their health goals, empowering them with information to discuss with their healthcare provider at their next visit.

The Path to $10B

FDA clearance of Lingo and Libre Rio is one element of Abbott’s path to grow the Libre portfolio to $10 billion in annual revenue by 2028, which we plan to do by:

• Expanding coverage by ensuring payers around the world recognize the value that Libre brings to patients, providers and healthcare systems.
• Expanding connectivity by partnering with other companies, from insulin delivery device manufacturers to other health and wellness leaders, to drive the next wave of diabetes innovation.
• Enhancing our existing offerings through ongoing improvements to the digital user experience and launching new features, such as our work to develop a sensor that monitors both glucose and ketone levels.
• Expanding into new consumer segments, as with Lingo empowering healthy people to stay healthy and have a deeper understanding of their metabolism. 

References

¹Data on file. Abbott Diabetes Care. Data based on the number of patients assigned to each manufacturer.

² Data on file. Abbott Diabetes Care.